Tazemetostat
Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438.  Tazemetaostat was granted FDA approval on 23 January 2020.